Insmed

Insmed helps people with rare and serious lung diseases breathe better. It makes specialized medicines for chronic infections that often have no other treatments. These therapies target deep-seated bacteria and inflammation to prevent permanent organ damage.

The Product Portfolio

• ARIKAYCE: Inhaled amikacin used to treat Mycobacterium avium complex (MAC) lung disease, a rare and chronic infection.
• BRINSUPRI: Oral tablet approved in 2025 for bronchiectasis, a condition where lung airways become permanently widened and damaged.
• TPIP: Investigational dry powder being tested for pulmonary arterial hypertension, which is high blood pressure in the lung vessels.
• Brensocatib: Small molecule drug currently in clinical trials for hidradenitis suppurativa, a painful and chronic inflammatory skin disease.
• Gene Therapy: Early-stage programs targeting rare muscle and nerve conditions like Duchenne muscular dystrophy and amyotrophic lateral sclerosis (ALS).

Strategic Moves and Acquisitions

• Acquired Opsidio in December 2025 to gain global rights for a new antibody therapy targeting respiratory and inflammatory diseases.
• Launched BRINSUPRI in the United States during the third quarter of 2025 following regulatory approval.
• Licensed global rights for brensocatib from AstraZeneca to develop treatments for chronic inflammatory lung conditions.
• Partnered with PPD Development to manage clinical trials for multiple pulmonary and immunology research programs through 2028.
• Collaborated with PARI Pharma to provide the specialized Lamira Nebulizer System required to deliver its inhaled medicines.

What Makes Insmed Unique

The company uses proprietary liposomal technology to deliver medicine directly into lung cells where infections live while reducing side effects in the rest of the body. It operates as a specialized global biopharmaceutical firm with a focus on three distinct areas: respiratory, immunology, and rare neurological diseases.

Tracking the Numbers

• Revenue reached $263.8 million in Q4 2025, a 152.6% increase compared to the previous year.
• Gross profit grew to $217.7 million in Q4 2025, up 178% from Q4 2024.
• Net income was a loss of $328.5 million in Q4 2025, compared to a loss of $235.5 million in Q4 2024.
• Market capitalization rose to $37.2 billion by the end of 2025, up 200.8% year-over-year.
• Free cash flow was negative $294.2 million in Q4 2025, down 45.1% from the $202.8 million loss in Q4 2024.

A Shifting Business Profile

Insmed has transitioned from a research-focused entity into a commercial-stage company with multiple approved products in the US and Europe. Its expansion into gene therapy and immunology marks a significant diversification beyond its original focus on rare lung infections.